EMA Checklist for annual updates for parallel distribution - Draft Guidance

June 23, 2022

22/06/2022
EMA/405782/2020 Rev. 3
Human Medicines Division

The European Medicines Agency (hereinafter 'the Agency') asks its applicants to use this checklist in advance of submission of an annual update for parallel distribution. You should be able to answer “Yes” to every item listed below unless a specific point is not applicable (“n/a”) to the application in question. In order to improve the quality of submissions, it is recommended to include the checklist with your submission.

Points 6 – 12 refer to the creation of scopes of change within an annual update. In case you are only updating the package leaflet and labelling and are not creating any additional scopes of change, please refer to points 1 – 5 only.

Upon receipt of an annual update for parallel distribution, the procedure manager proceeds to validate the documentation submitted in accordance with the checklist included below.

Updates to the information included in the IRIS form after submission of any notification for parallel distribution are only possible in exceptional cases, so the applicants should review the information included in the form carefully before submitting. Changes impacting fees would not be possible after submission. Only changes requested by the assessor would be possible and only by exception when properly justified.

Reference documents for further information

  • Parallel distribution regulatory and procedural guidance:

https://www.ema.europa.eu/en/human-regulatory/post-authorisation/parallel-distribution/

  • Frequently asked questions (FAQs) about parallel distribution:

https://www.ema.europa.eu/en/human-regulatory/post-authorisation/parallel-distribution/frequently-asked-questions-about-parallel-distribution

  • Public register of parallel distribution notices:

https://iris.ema.europa.eu/registerpd/

Download Checklist

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.




pesticides Europe

July 5, 2022

Draft report on the development of a harmonised approach to exposure assessment methodologies for residues from veterinary medicinal products, feed additives and pesticides in food of animal origin

In 2020, the European Commission (EC) requested EMA and European Food Safety Authority (EFSA) for advice for the development of a harmonised approach on exposure assessment methodologies for residues...

Read the Full Article
EMA EU

April 26, 2022

Facilitating global access to diabetes treatments for non-EU patients Share

April 22, 2022 EMA’s human medicines committee (CHMP) has given a recommendation for two diabetes mellitus treatments, Actrapid and Insulatard, for use outside the European Union (EU). EMA is...

Read the Full Article
EMA Europe

June 20, 2022

Validation checklist for initial marketing authorisation applications - biologicals other than immunologicals (applicable to submissions under Regulation (EU) 2019/6)

JUNE 2022 EMA/278419/2022-Rev.1 This validation checklist is used by the Agency to validate initial marketing authorization applications for pharmaceuticals and applicants should use it as a means to...

Read the Full Article